Overview

A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma

Status:
Recruiting

Trial end date:
2026-06-28

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the efficacy and safety of pemigatinib versus gemcitabine plus cisplatin chemotherapy in first-line treatment of participants with unresectable or metastatic cholangiocarcinoma with FGFR2 rearrangement.

Phase:

Phase 3

Details

Lead Sponsor:

Incyte Corporation

Treatments:

Cisplatin
Gemcitabine